TY - JOUR
T1 - The effect of soaking allograft in bisphosphonate
T2 - A pilot dose-response study
AU - Jakobsen, Thomas
AU - Baas, Jørgen
AU - Bechtold, Joan E.
AU - Elmengaard, Brian
AU - Søballe, Kjeld
PY - 2010/3
Y1 - 2010/3
N2 - Background: Long-term survival of uncemented total joint replacements relies on osseointegration. With reduced bone stock impacted morselized allograft enhances early implant fixation but is subject to resorption. Purpose: We therefore asked whether soaking morselized allograft in different concentrations of bisphosphonate before impaction would enhance fixation. Methods: In each of 10 dogs, we implanted four unloaded titanium implants surrounded by a 2.5-mm gap into the proximal humerus, two implants in each humerus. The gap was filled with impacted morselized allograft soaked in saline or a low-, middle-, or high-dose bisphosphonate solution (0.005, 0.05, or 0.5 mg zoledronate/mL). At 4 weeks, the implants were evaluated by histomorphometric analysis and mechanical pushout test. Results: The low dose of zoledronate increased new bone formation in the allograft but the high dose decreased new bone formation. The high dose of zoledronate resulted in the greatest inhibition of allograft resorption, whereas the low dose of zoledronate resulted in the lowest inhibition of allograft resorption. Implants surrounded allograft soaked in the low dose of zoledronate or saline had better fixation for all three mechanical parameters compared with implants surrounded by allograft soaked in the middle or high dose of zoledronate. Conclusions: These data suggest bisphosphonate may enhance osseointegration of allografted implants and emphasize the need for preclinical testing of antiresorptive therapies.
AB - Background: Long-term survival of uncemented total joint replacements relies on osseointegration. With reduced bone stock impacted morselized allograft enhances early implant fixation but is subject to resorption. Purpose: We therefore asked whether soaking morselized allograft in different concentrations of bisphosphonate before impaction would enhance fixation. Methods: In each of 10 dogs, we implanted four unloaded titanium implants surrounded by a 2.5-mm gap into the proximal humerus, two implants in each humerus. The gap was filled with impacted morselized allograft soaked in saline or a low-, middle-, or high-dose bisphosphonate solution (0.005, 0.05, or 0.5 mg zoledronate/mL). At 4 weeks, the implants were evaluated by histomorphometric analysis and mechanical pushout test. Results: The low dose of zoledronate increased new bone formation in the allograft but the high dose decreased new bone formation. The high dose of zoledronate resulted in the greatest inhibition of allograft resorption, whereas the low dose of zoledronate resulted in the lowest inhibition of allograft resorption. Implants surrounded allograft soaked in the low dose of zoledronate or saline had better fixation for all three mechanical parameters compared with implants surrounded by allograft soaked in the middle or high dose of zoledronate. Conclusions: These data suggest bisphosphonate may enhance osseointegration of allografted implants and emphasize the need for preclinical testing of antiresorptive therapies.
UR - http://www.scopus.com/inward/record.url?scp=77449130865&partnerID=8YFLogxK
U2 - 10.1007/s11999-009-1099-9
DO - 10.1007/s11999-009-1099-9
M3 - Article
C2 - 19763718
AN - SCOPUS:77449130865
SN - 0009-921X
VL - 468
SP - 867
EP - 874
JO - Clinical Orthopaedics and Related Research
JF - Clinical Orthopaedics and Related Research
IS - 3
ER -